Ken Griffin Larimar Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 24,100 shares of LRMR stock, worth $96,159. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,100
Previous 36,500
33.97%
Holding current value
$96,159
Previous $264,000
40.53%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding LRMR
# of Institutions
128Shares Held
67.3MCall Options Held
280KPut Options Held
76.3K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$84.7 Million2.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$24.1 Million0.55% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$22.2 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.25MShares$17 Million0.0% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.17MShares$16.6 Million9.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $173M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...